Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac® (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD)

NCT04289103 is registered in ClinicalTrials.gov with ElsaLys Biotech as lead sponsor.

NCT NCT04289103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04289103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac® (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD)
Lead sponsor
ElsaLys Biotech
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2021
Completion date
June 30, 2024
Enrollment
65 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

steroid refractory gvhd